Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.

There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout the industry regarding the true expense of bringing a drug from bench ...

HMNC has completed the subject randomisation in its Phase IIb OLIVE trial of BH-200 for major depressive disorder (MDD) treatment.

The announcement follows just days after the US Centres for Disease Control confirmed its first death from Avian Influenza.

Alentis Therapeutics has reported positive topline outcomes from two clinical trials of lixudebart (ALE.F02) for reversing organ fibrosis.

IO Biotech has finished enrolling subjects in a Phase II trial of IO102-IO103 in conjunction with MSD's KEYTRUDA (pembrolizumab).

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Contineum Therapeutics has concluded targeted enrolment in a Phase II trial of PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.